NEW YORK (GenomeWeb) – Agilent Technologies and Agendia announced today that they have partnered to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

Under the terms of the deal, the companies will use Agilent's SureSelect target enrichment system to develop an RNA sequencing kit version of Agendia's microarray-based MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.